Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention

Experimental Neurology

Volumn 208, Issue 1, 2007, Pages 1-25

  Tansey, Malú G ^a   McCoy, Melissa K ^a   Frank Cannon, Tamy C ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Anti inflammatory therapy; Cytokines; Dopamine neuron death; IL 1 ; Microglia activation; Neurodegeneration; Neuroinflammation; Oxidative stress; Parkinson's disease; TNF

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ANTIINFLAMMATORY AGENT; COLONY STIMULATING FACTOR 1; CYCLOSPORIN A; HYDROGEN PEROXIDE; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 3; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MINOCYCLINE; MONOAMINE OXIDASE B INHIBITOR; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; OXIDOPAMINE; PARGYLINE; PENTOXIFYLLINE; PEROXYNITRITE; PROSTAGLANDIN E2; SALICYLATE SODIUM; SELEGILINE; SILYMARIN; SUPEROXIDE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ATHEROSCLEROSIS; CELL RESPIRATION; CHEMOTAXIS; CLINICAL TRIAL; DIGESTIVE SYSTEM INFLAMMATION; DISEASE ASSOCIATION; DRUG TARGETING; EPIGENETICS; HUMAN; IN VIVO STUDY; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MICROGLIA; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; STRIATONIGRAL DEGENERATION; STRUCTURE ACTIVITY RELATION; T LYMPHOCYTE; TRAUMATIC BRAIN INJURY; VIRUS ENCEPHALITIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL SURVIVAL; CORPUS STRIATUM; DOPAMINE; ENVIRONMENT; EPIGENESIS, GENETIC; HUMANS; INFLAMMATION; NERVOUS SYSTEM DISEASES; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 35348966882     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2007.07.004     Document Type: Review

References (328)

1. Akhmedova S.N., Yakimovsky A.K., and Schwartz E.I. Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson's disease. J. Neurol. Sci. 184 (2001) 179-182
2. Allan S.M., Tyrrell P.J., and Rothwell N.J. Interleukin-1 and neuronal injury. Nat. Rev., Immunol. 5 (2005) 629-640
3. Aloe L., and Fiore M. TNF-alpha expressed in the brain of transgenic mice lowers central thyroxine hydroxylase immunoreactivity and alters grooming behavior. Neurosci. Lett. 238 (1997) 65-68
4. Aloisi F. The role of microglia and astrocytes in CNS immune surveillance and immunopathology. Adv. Exp. Med. Biol. 468 (1999) 123-133
5. Aloisi F. Immune function of microglia. Glia 36 (2001) 65-179
6. Aloisi F., Serafini B., and Adorini L. Glia-T cell dialogue. J. Neuroimmunol. 107 (2000) 111-117
7. Arai H., Furuya T., Yasuda T., Miura M., Mizuno Y., and Mochizuki H. Neurotoxic effects of lipopolysaccharide on nigral dopaminergic neurons are mediated by microglial activation, interleukin-1beta, and expression of caspase-11 in mice. J. Biol. Chem. 279 (2004) 51647-51653
8. Arai H., Furuya T., Mizuno Y., and Mochizuki H. Inflammation and infection in Parkinson's disease. Histol. Histopathol. 21 (2006) 673-678
9. Arimoto T., and Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol. Dis. 12 (2003) 35-45
10. Austin S.A., Floden A.M., Murphy E.J., and Combs C.K. Alpha-synuclein expression modulates microglial activation phenotype. J. Neurosci. 26 (2006) 10558-10563
11. Banati R.B., Daniel S.E., and Blunt S.B. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov. Disord. 13 (1998) 221-227
12. Barcia C., Fernandez Barreiro A., Poza M., and Herrero M.T. Parkinson's disease and inflammatory changes. Neurotox. Res. 5 (2003) 411-418
13. Barcia C., de Pablos V., Bautista-Hernandez V., Sanchez-Bahillo A., Bernal I., Fernandez-Villalba E., Martin J., Banon R., Fernandez-Barreiro A., and Herrero M.T. Increased plasma levels of TNF-alpha but not of IL1-beta in MPTP-treated monkeys one year after the MPTP administration. Parkinsonism Relat. Disord. 11 (2005) 435-439
14. Batchelor P.E., Liberatore G.T., Wong J.Y., Porritt M.J., Frerichs F., Donnan G.A., and Howells D.W. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 19 (1999) 1708-1716
15. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58 (2005) 495-505
16. Beckman J.S., Beckman T.W., Chen J., Marshall P.A., and Freeman B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 1620-1624
17. Benner E.J., Mosley R.L., Destache C.J., Lewis T.B., Jackson-Lewis V., Gorantla S., Nemachek C., Green S.R., Przedborski S., and Gendelman H.E. Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 9435-9440
18. Bernardino L., Xapelli S., Silva A.P., Jakobsen B., Poulsen F.R., Oliveira C.R., Vezzani A., Malva J.O., and Zimmer J. Modulator effects of interleukin-1beta and tumor necrosis factor-alpha on AMPA-induced excitotoxicity in mouse organotypic hippocampal slice cultures. J. Neurosci. 25 (2005) 6734-6744
19. Bessler H., Djaldetti R., Salman H., Bergman M., and Djaldetti M. IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed. Pharmacother. 53 (1999) 141-145
20. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
21. Beyer M., Gimsa U., Eyupoglu I.Y., Hailer N.P., and Nitsch R. Phagocytosis of neuronal or glial debris by microglial cells: upregulation of MHC class II expression and multinuclear giant cell formation in vitro. Glia 31 (2000) 262-266
22. Bialecka M., Kurzawski M., Klodowska-Duda G., Opala G., Juzwiak S., Kurzawski G., Tan E.K., and Drozdzik M. CARD15 variants in patients with sporadic Parkinson's disease. Neurosci. Res. 57 (2007) 473-476
23. Block M.L., and Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76 (2005) 77-98
24. Blum-Degen D., Muller T., Kuhn W., Gerlach M., Przuntek H., and Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci. Lett. 202 (1995) 17-20
25. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., and Verna J.M. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65 (2001) 135-172
26. Bohatschek M., Werner A., and Raivich G. Systemic LPS injection leads to granulocyte influx into normal and injured brain: effects of ICAM-1 deficiency. Exp. Neurol. 172 (2001) 137-152
27. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., and Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 172 (1994) 151-154
28. Bonen D.K., and Cho J.H. The genetics of inflammatory bowel disease. Gastroenterology 124 (2003) 521-536
29. Bonifati V., Rizzu P., Squitieri F., Krieger E., Vanacore N., van Swieten J.C., Brice A., van Duijn C.M., Oostra B., Meco G., and Heutink P. DJ-1 (PARK7), a novel gene for autosomal recessive, early onset parkinsonism. Neurol. Sci. 24 (2003) 159-160
30. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., and Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 (2003) 256-259
31. Breder C.D., Tsujimoto M., Terano Y., Scott D.W., and Saper C.B. Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J. Comp. Neurol. 337 (1993) 543-567
32. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J. Neurochem. 82 (2002) 615-624
33. Bronstein D.M., Perez-Otano I., Sun V., Mullis Sawin S.B., Chan J., Wu G.C., Hudson P.M., Kong L.Y., Hong J.S., and McMillian M.K. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res. 704 (1995) 112-116
34. Caboni P., Sherer T.B., Zhang N., Taylor G., Na H.M., Greenamyre J.T., and Casida J.E. Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease. Chem. Res. Toxicol. 17 (2004) 1540-1548
35. Camandola S., and Mattson M.P. NF-kappa B as a therapeutic target in neurodegenerative diseases. Expert Opin. Ther. Targets 11 (2007) 123-132
36. Carvey P.M., Chang Q., Lipton J.W., and Ling Z. Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. Front. Biosci. 8 (2003) s826-s837
37. Carvey P.M., Chen E.Y., Lipton J.W., Tong C.W., Chang Q.A., and Ling Z.D. Intra-parenchymal injection of tumor necrosis factor-alpha and interleukin 1-beta produces dopamine neuron loss in the rat. J. Neural Transm. 112 (2005) 601-612
38. Casals J., Elizan T.S., and Yahr M.D. Postencephalitic parkinsonism-a review. J. Neural Transm. 105 (1998) 645-676
39. Cassarino D.S., Fall C.P., Swerdlow R.H., Smith T.S., Halvorsen E.M., Miller S.W., Parks J.P., Parker Jr. W.D., and Bennett Jr. J.P. Elevated reactive oxygen species and antioxidant enzyme activities in animal and cellular models of Parkinson's disease. Biochim. Biophys. Acta 1362 (1997) 77-86
40. Castano A., Herrera A.J., Cano J., and Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 70 (1998) 1584-1592
41. Castano A., Herrera A.J., Cano J., and Machado A. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. J. Neurochem. 81 (2002) 150-157
42. Chen H., Zhang S.M., Hernan M.A., Schwarzschild M.A., Willett W.C., Colditz G.A., Speizer F.E., and Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch. Neurol. 60 (2003) 1059-1064
43. Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., and Ascherio A. Nonsteroidal antiinflammatory drug use and the risk of Parkinson's disease. Ann. Neurol. 59 (2005) 988-989
44. Chen X., Ding W.X., Ni H.M., Gao W., Shi Y.H., Gambotto A.A., Fan J., Beg A.A., and Yin X.M. Bid-independent mitochondrial activation in tumor necrosis factor alpha-induced apoptosis and liver injury. Mol. Cell. Biol. 27 (2007) 541-553
45. Choi H.J., Lee S.Y., Cho Y., No H., Kim S.W., and Hwang O. Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: implications for Parkinson's disease. Neurochem. Int. 48 (2006) 255-262
46. Cicchetti F., Brownell A.L., Williams K., Chen Y.I., Livni E., and Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur. J. Neurosci. 15 (2002) 991-998
47. Clarke D.J., and Branton R.L. A role for tumor necrosis factor alpha in death of dopaminergic neurons following neural transplantation. Exp. Neurol. 176 (2002) 154-162
48. Cleren C., Calingasan N.Y., Chen J., and Beal M.F. Celastrol protects against MPTP- and 3-nitropropionic acid-induced neurotoxicity. J. Neurochem. 94 (2005) 995-1004
49. Consilvio C., Vincent A.M., and Feldman E.L. Neuroinflammation, COX-2, and ALS-a dual role?. Exp. Neurol. 187 (2004) 1-10
50. Cookson M.R. Pathways to Parkinsonism. Neuron 37 (2003) 7-10
51. Corti O., Hampe C., Darios F., Ibanez P., Ruberg M., and Brice A. Parkinson's disease: from causes to mechanisms. C. R. Biol. 328 (2005) 131-142
52. Czlonkowska A., Kohutnicka M., Kurkowska-Jastrzebska I., and Czlonkowski A. Microglial reaction in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) induced Parkinson's disease mice model. Neurodegeneration 5 (1996) 137-143
53. Dale R.C., Church A.J., Surtees R.A., Lees A.J., Adcock J.E., Harding B., Neville B.G., and Giovannoni G. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 127 (2004) 21-33
54. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
55. Dawson T.M., Zhang J., Dawson V.L., and Snyder S.H. Nitric oxide: cellular regulation and neuronal injury. Prog. Brain Res. 103 (1994) 365-369
56. Dbaibo G.S., Obeid L.M., and Hannun Y.A. Tumor necrosis factor-alpha (TNF-alpha) signal transduction through ceramide. Dissociation of growth inhibitory effects of TNF-alpha from activation of nuclear factor-kappa B. J. Biol. Chem. 268 (1993) 17762-17766
57. De Pablos R.M., Herrera A.J., Villaran R.F., Cano J., and Machado A. Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB J. 19 (2005) 407-409
58. De Smaele E., Zazzeroni F., Papa S., Nguyen D.U., Jin R., Jones J., Cong R., and Franzoso G. Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature 414 (2001) 308-313
59. Dehmer T., Lindenau J., Haid S., Dichgans J., and Schulz J.B. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J. Neurochem. 74 (2000) 2213-2216
60. Delgado M., and Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation. FASEB J. 17 (2003) 944-946
61. Delgado M., and Ganea D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 17 (2003) 1922-1924
62. Deng H., Le W.D., Hunter C.B., Ondo W.G., Guo Y., Xie W.J., and Jankovic J. Heterogeneous phenotype in a family with compound heterozygous parkin gene mutations. Arch. Neurol. 63 (2006) 273-277
63. Depino A., Ferrari C., Pott Godoy M.C., Tarelli R., and Pitossi F.J. Differential effects of interleukin-1beta on neurotoxicity, cytokine induction and glial reaction in specific brain regions. J. Neuroimmunol. 168 (2005) 96-110
64. Dobbs R.J., Charlett A., Dobbs S.M., Weller C., and Peterson D.W. Parkinsonism: differential age-trend in Helicobacter pylori antibody. Aliment. Pharmacol. Ther. 14 (2000) 1199-1205
65. Dopp J.M., Mackenzie-Graham A., Otero G.C., and Merrill J.E. Differential expression, cytokine modulation, and specific functions of type-1 and type-2 tumor necrosis factor receptors in rat glia. J. Neuroimmunol. 75 (1997) 104-112
66. Du Y., Ma Z., Lin S., Dodel R.C., Gao F., Bales K.R., Triarhou L.C., Chernet E., Perry K.W., Nelson D.L., Luecke S., Phebus L.A., Bymaster F.P., and Paul S.M. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14669-14674
67. Duke D.C., Moran L.B., Pearce R.K., and Graeber M.B. The medial and lateral substantia nigra in Parkinson's disease: mRNA profiles associated with higher brain tissue vulnerability. Neurogenetics 8 (2007) 83-94
68. Esposito E., Di Matteo V., Benigno A., Pierucci M., Crescimanno G., and Di Giovanni G. Non-steroidal anti-inflammatory drugs in Parkinson's disease. Exp. Neurol. 205 (2007) 295-312
69. Factor S.A., and Weiner W.J. Prior history of head trauma in Parkinson's disease. Mov. Disord. 6 (1991) 225-229
70. Fahn S. Description of Parkinson's disease as a clinical syndrome. Ann. N. Y. Acad. Sci. 991 (2003) 1-14
71. Fan J., and Watanabe T. Inflammatory reactions in the pathogenesis of atherosclerosis. J. Atheroscler. Thromb. 10 (2003) 63-71
72. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev., Genet. 7 (2006) 306-318
73. Feng Z.H., Wang T.G., Li D.D., Fung P., Wilson B.C., Liu B., Ali S.F., Langenbach R., and Hong J.S. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl 1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett. 329 (2002) 354-358
74. Ferger B., Leng A., Mura A., Hengerer B., and Feldon J. Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum. J. Neurochem. 89 (2004) 822-833
75. Fernandez-Checa J.C. Alcohol-induced liver disease: when fat and oxidative stress meet. Ann. Hepatol. 2 (2003) 69-75
76. Fernandez-Checa J.C., and Kaplowitz N. Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol. Appl. Pharmacol. 204 (2005) 263-273
77. Fernandez-Checa J.C., Kaplowitz N., Garcia-Ruiz C., Colell A., Miranda M., Mari M., Ardite E., and Morales A. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am. J. Physiol. 273 (1997) G7-G17
78. Fernandez-Checa J.C., Kaplowitz N., Garcia-Ruiz C., and Colell A. Mitochondrial glutathione: importance and transport. Semin. Liver Dis. 18 (1998) 389-401
79. Ferrari C.C., Pott Godoy M.C., Tarelli R., Chertoff M., Depino A.M., and Pitossi F.J. Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1beta in the substantia nigra. Neurobiol. Dis. 24 (2006) 183-193
80. Figueiredo-Pereira M.E., Li Z., Jansen M., and Rockwell P. N-Acetylcysteine and celecoxib lessen cadmium cytotoxicity which is associated with cyclooxygenase-2 up-regulation in mouse neuronal cells. J. Biol. Chem. 277 (2002) 25283-25289
81. Firestone J.A., Smith-Weller T., Franklin G., Swanson P., Longstreth Jr. W.T., and Checkoway H. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch. Neurol. 62 (2005) 91-95
82. Floor E., and Wetzel M.G. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70 (1998) 268-275
83. Floyd R.A. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222 (1999) 236-245
84. Gandhi S., Muqit M.M., Stanyer L., Healy D.G., Abou-Sleiman P.M., Hargreaves I., Heales S., Ganguly M., Parsons L., Lees A.J., Latchman D.S., Holton J.L., Wood N.W., and Revesz T. PINK1 protein in normal human brain and Parkinson's disease. Brain 129 (2006) 1720-1731
85. Gao H.M., Hong J.S., Zhang W., and Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22 (2002) 782-790
86. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., and Liu B. Microglial activation-mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81 (2002) 1285-1297
87. Gao H.M., Liu B., Zhang W., and Hong J.S. Novel anti-inflammatory therapy for Parkinson's disease. Trends Pharmacol. Sci. 24 (2003) 395-401
88. Garcia-Ruiz C., and Fernandez-Checa J.C. Mitochondrial glutathione: hepatocellular survival-death switch. J. Gastroenterol. Hepatol. 21 Suppl 3 (2006) S3-S6
89. Gayle D.A., Ling Z., Tong C., Landers T., Lipton J.W., and Carvey P.M. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res. Dev. Brain Res. 133 (2002) 27-35
90. 11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol. Dis. 21 (2006) 404-412
91. German D.C., Speciale S.G., Manaye K.F., and Sadeq M. Opioid receptors in midbrain dopaminergic regions of the rat: I. Mu receptor autoradiography. J. Neural Transm. Gen. Sect. 91 (1993) 39-52
92. Ghione I., Di Fonzo A., Saladino F., Del Bo R., Bresolin N., Comi G.P., and Rango M. Parkin polymorphisms and environmental exposure: decrease in age at onset of Parkinson's disease. Neurotoxicology 28 (2007) 698-701
93. Gold B.G., and Nutt J.G. Neuroimmunophilin ligands in the treatment of Parkinson's disease. Curr. Opin. Pharmacol. 2 (2002) 82-86
94. Goldman S.M., Tanner C.M., Oakes D., Bhudhikanok G.S., Gupta A., and Langston J.W. Head injury and Parkinson's disease risk in twins. Ann. Neurol. 60 (2006) 65-72
95. Graham D.G. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14 (1978) 633-643
96. Grigoryan G.A., Gray J.A., Rashid T., Chadwick A., and Hodges H. Conditionally immortal neuroepithelial stem cell grafts restore spatial learning in rats with lesions at the source of cholinergic forebrain projections cholinergic forebrain projections. Restor. Neurol. Neurosci. 17 (2000) 1
97. Gross A., Yin X.M., Wang K., Wei M.C., Jockel J., Milliman C., Erdjument-Bromage H., Tempst P., and Korsmeyer S.J. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274 (1999) 1156-1163
98. Hakansson A., Westberg L., Nilsson S., Buervenich S., Carmine A., Holmberg B., Sydow O., Olson L., Johnels B., Eriksson E., and Nissbrandt H. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 133 (2005) 88-92
99. Hakansson A., Westberg L., Nilsson S., Buervenich S., Carmine A., Holmberg B., Sydow O., Olson L., Johnels B., Eriksson E., and Nissbrandt H. Investigation of genes coding for inflammatory components in Parkinson's disease. Mov. Disord. 20 (2005) 569-573
100. Hald A., and Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Exp. Neurol. 193 (2005) 279-290
101. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J. Neurochem. 97 (2006) 1634-1658
102. Hamaue N., Ogata A., Terado M., Ohno K., Kikuchi S., Sasaki H., Tashiro K., Hirafuji M., and Minami M. Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat induced by Japanese encephalitis virus. Neurochem. Res. 31 (2006) 1451-1455
103. Hannun Y.A., Obeid L.M., and Wolff R.A. The novel second messenger ceramide: identification, mechanism of action, and cellular activity. Adv. Lipid Res. 25 (1993) 43-64
104. Hasegawa Y., Inagaki T., Sawada M., and Suzumura A. Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease. Acta Neurol. Scand. 101 (2000) 159-164
105. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64 (1995) 919-924
106. Haupt C., Witte O.W., and Frahm C. Up-regulation of Connexin43 in the glial scar following photothrombotic ischemic injury. Mol. Cell. Neurosci. 35 (2007) 89-99
107. He Y., Appel S., and Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909 (2001) 187-193
108. Heldmann U., Thored P., Claasen J.H., Arvidsson A., Kokaia Z., and Lindvall O. TNF-alpha antibody infusion impairs survival of stroke-generated neuroblasts in adult rat brain. Exp. Neurol. 196 (2005) 204-208
109. Hemmer K., Fransen L., Vanderstichele H., Vanmechelen E., and Heuschling P. An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha. Neurochem. Int. 38 (2001) 557-565
110. Henn I.H., Bouman L., Schlehe J.S., Schlierf A., Schramm J.E., Wegener E., Nakaso K., Culmsee C., Berninger B., Krappmann D., Tatzelt J., and Winklhofer K.F. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. J. Neurosci. 27 (2007) 1868-1878
111. Herrera A.J., Castano A., Venero J.L., Cano J., and Machado A. The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol. Dis. 7 (2000) 429-447
112. Herrera A.J., Tomas-Camardiel M., Venero J.L., Cano J., and Machado A. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. J. Neural Transm. 112 (2005) 111-119
113. Hirsch E.C., Faucheux B., Damier P., Mouatt-Prigent A., and Agid Y. Neuronal vulnerability in Parkinson's disease. J. Neural Transm., Suppl. 50 (1997) 79-88
114. Hirsch E.C., Hunot S., Damier P., and Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. Ann. Neurol. 44 (1998) S115-S120
115. Hirsch E.C., Breidert T., Rousselet E., Hunot S., Hartmann A., and Michel P.P. The role of glial reaction and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci. 991 (2003) 214-228
116. Hirsch E.C., Hunot S., and Hartmann A. Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat. Disord. 11 Suppl 1 (2005) S9-S15
117. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., Binder V., Finkel Y., Cortot A., Modigliani R., Laurent-Puig P., Gower-Rousseau C., Macry J., Colombel J.F., Sahbatou M., and Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
118. Hunot S., Brugg B., Ricard D., Michel P.P., Muriel M.P., Ruberg M., Faucheux B.A., Agid Y., and Hirsch E.C. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 7531-7536
119. Hunot S., Dugas N., Faucheux B., Hartmann A., Tardieu M., Debre P., Agid Y., Dugas B., and Hirsch E.C. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J. Neurosci. 19 (1999) 3440-3447
120. Inohara N., and Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat. Rev., Immunol. 3 (2003) 371-382
121. Iravani M.M., Kashefi K., Mander P., Rose S., and Jenner P. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience 110 (2002) 49-58
122. Irizarry M.C., Kim T.W., McNamara M., Tanzi R.E., George J.M., Clayton D.F., and Hyman B.T. Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J. Neuropathol. Exp. Neurol. 55 (1996) 889-895
123. Isacson O. Models of repair mechanisms for future treatment modalities of Parkinson's disease. Brain Res. Bull. 57 (2002) 839-846
124. Ito S., Sawada M., Haneda M., Ishida Y., and Isobe K.I. Amyloid-beta peptides induce several chemokine mRNA expressions in the primary microglia and Ra2 cell line via the PI3K/Akt and/or ERK pathway. Neurosci. Res. 56 (2006) 294-299
125. Jackson-Lewis V., and Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nat. Protoc. 2 (2007) 141-151
126. Jankovic J. Searching for a relationship between manganese and welding and Parkinson's disease. Neurology 64 (2005) 2021-2028
127. Jenner P., and Olanow C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 47 (1996) S161-S170
128. Jenner P., and Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 44 (1998) S72-S84
129. 2 receptor subtype 2 (EP2) regulates microglial activation and associated neurotoxicity induced by aggregated alpha-synuclein. J. Neuroinflammation 4 (2007) 2
130. Josephs K.A., Parisi J.E., and Dickson D.W. Alpha-synuclein studies are negative in postencephalic parkinsonism of von Economo. Neurology 59 (2002) 645-646
131. Ju W., and Neufeld A. Cellular localization of cyclooxygenase-1 and cyclooxygenase-2 in the normal mouse, rat, and human retina. J. Comp. Neurol. 452 (2002) 392-399
132. Jung Y., and Surh Y. Oxidative DNA damage and cytotoxicity induced by copper-stimulated redox cycling of salsolinol, a neurotoxic tetrahydroisoquinoline alkaloid. Free Radic. Biol. Med. 30 (2001) 1407-1417
133. Jurewicz A., Matysiak M., Tybor K., and Selmaj K. TNF-induced death of adult human oligodendrocytes is mediated by c-jun NH2-terminal kinase-3. Brain 126 (2003) 1358-1370
134. Kahle P.J., Neumann M., Ozmen L., Muller V., Jacobsen H., Schindzielorz A., Okochi M., Leimer U., van Der Putten H., Probst A., Kremmer E., Kretzschmar H.A., and Haass C. Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha-synuclein in human and transgenic mouse brain. J. Neurosci. 20 (2000) 6365-6373
135. Kaltschmidt B., Widera D., and Kaltschmidt C. Signaling via NF-kappaB in the nervous system. Biochim. Biophys. Acta 1745 (2005) 287-299
136. Kamel F., Tanner C., Umbach D., Hoppin J., Alavanja M., Blair A., Comyns K., Goldman S., Korell M., Langston J., Ross G., and Sandler D. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am. J. Epidemiol. 165 (2007) 364-374
137. Keeney P.M., Xie J., Capaldi R.A., and Bennett Jr. J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J. Neurosci. 26 (2006) 5256-5264
138. Kim S.U., and de Vellis J. Microglia in health and disease. J. Neurosci. Res. 81 (2005) 302-313
139. Kim Y.S., and Joh T.H. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp. Mol. Med. 38 (2006) 333-347
140. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., and Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20 (2000) 6309-6316
141. Kirik D., Rosenblad C., and Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp. Neurol. 152 (1998) 259-277
142. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., and Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (1998) 605-608
143. Kitada T., Pisani A., Porter D.R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E.N., and Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 11441-11446
144. Klegeris A., and McGeer P.L. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Exp. Neurol. 166 (2000) 458-464
145. Klegeris A., Pelech S., Giasson B.I., Maguire J., Zhang H., McGeer E.G., and McGeer P.L. alpha-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia. Neurobiol. Aging 20 (2006) 2000-2008
146. Kloss C.U., Bohatschek M., Kreutzberg G.W., and Raivich G. Effect of lipopolysaccharide on the morphology and integrin immunoreactivity of ramified microglia in the mouse brain and in cell culture. Exp. Neurol. 168 (2001) 32-46
147. Kohutnicka M., Lewandowska E., Kurkowska-Jastrzebska I., Czlonkowski A., and Czlonkowska A. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39 (1998) 167-180
148. Kortekaas R., Leenders K.L., van Oostrom J.C., Vaalburg W., Bart J., Willemsen A.T., and Hendrikse N.H. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 57 (2005) 176-179
149. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19 (1996) 312-318
150. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., and Schapira A.H. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann. Neurol. 32 (1992) 782-788
151. Kruger R., Hardt C., Tschentscher F., Jackel S., Kuhn W., Muller T., Werner J., Woitalla D., Berg D., Kuhnl N., Fuchs G.A., Santos E.J., Przuntek H., Epplen J.T., Schols L., and Riess O. Genetic analysis of immunomodulating factors in sporadic Parkinson's disease. J. Neural Transm. 107 (2000) 553-562
152. Kurkowska-Jastrzebska I., Litwin T., Joniec I., Ciesielska A., Przybylkowski A., Czlonkowski A., and Czlonkowska A. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. Int. Immunopharmacol. 4 (2004) 1307-1318
153. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., and Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann. Neurol. 46 (1999) 598-605
154. Lansbury Jr. P.T., and Brice A. Genetics of Parkinson's disease and biochemical studies of implicated gene products. Curr. Opin. Cell Biol. 14 (2002) 653-660
155. Lansbury P.T., and Lashuel H.A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443 (2006) 774-779
156. + T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neuroimmunol. 183 (2007) 60-68
157. Lawrence T., Gilroy D.W., Colville-Nash P.R., and Willoughby D.A. Possible new role for NF-kappaB in the resolution of inflammation. Nat. Med. 7 (2001) 1291-1297
158. Lawson L.J., Perry V.H., Dri P., and Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39 (1990) 151-170
159. Le W., Rowe D., Xie W., Ortiz I., He Y., and Appel S.H. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 21 (2001) 8447-8455
160. Leng A., Mura A., Feldon J., and Ferger B. Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease. Neurosci. Lett. 375 (2005) 107-111
161. Li Z., Jansen M., Pierre S.R., and Figueiredo-Pereira M.E. Neurodegeneration: linking ubiquitin/proteasome pathway impairment with inflammation. Int. J. Biochem. Cell. Biol. 35 (2003) 547-552
162. Li Z., Jansen M., Ogburn K., Salvatierra L., Hunter L., Mathew S., and Figueiredo-Pereira M.E. Neurotoxic prostaglandin J2 enhances cyclooxygenase-2 expression in neuronal cells through the p38MAPK pathway: a death wish?. J. Neurosci. Res. 78 (2004) 824-836
163. Li Z., Melandri F., Berdo I., Jansen M., Hunter L., Wright S., Valbrun D., and Figueiredo-Pereira M.E. Delta12-prostaglandin J2 inhibits the ubiquitin hydrolase UCH-L1 and elicits ubiquitin-protein aggregation without proteasome inhibition. Biochem. Biophys. Res. Commun. 319 (2004) 1171-1180
164. Li W., West N., Colla E., Pletnikova O., Troncoso J.C., Marsh L., Dawson T.M., Jakala P., Hartmann T., Price D.L., and Lee M.K. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 2162-2167
165. Liang Z.Q., Li Y.L., Zhao X.L., Han R., Wang X.X., Wang Y., Chase T.N., Bennett M.C., and Qin Z.H. NF-kappaB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53. Brain Res. 1145 (2007) 190-203
166. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., and Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5 (1999) 1403-1409
167. Lin M.T., and Beal M.F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443 (2006) 787-795
168. Lin S., Wei X., Xu Y., Yan C., Dodel R., Zhang Y., Liu J., Klaunig J.E., Farlow M., and Du Y. Minocycline blocks 6-hydroxydopamine-induced neurotoxicity and free radical production in rat cerebellar granule neurons. Life Sci. 72 (2003) 1635-1641
169. Linda H., Hammarberg H., Piehl F., Khademi M., and Olsson T. Expression of MHC class I heavy chain and beta2-microglobulin in rat brainstem motoneurons and nigral dopaminergic neurons. J. Neuroimmunol. 101 (1999) 76-86
170. Ling Z.D., Potter E.D., Lipton J.W., and Carvey P.M. Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp. Neurol. 149 (1998) 411-423
171. 3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures. J. Pharmacol. Exp. Ther. 289 (1999) 202-210
172. Ling Z., Gayle D.A., Ma S.Y., Lipton J.W., Tong C.W., Hong J.S., and Carvey P.M. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov. Disord. 17 (2002) 116-124
173. Ling Z., Zhu Y., Tong C., Snyder J.A., Lipton J.W., and Carvey P.M. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp. Neurol. 199 (2006) 499-512
174. Liu Z.G. Molecular mechanism of TNF signaling and beyond. Cell Res. 15 (2005) 24-27
175. Liu B., and Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304 (2003) 1-7
176. Liu B., Andrieu-Abadie N., Levade T., Zhang P., Obeid L.M., and Hannun Y.A. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J. Biol. Chem. 273 (1998) 11313-11320
177. Liu B., Du L., and Hong J.S. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J. Pharmacol. Exp. Ther. 293 (2000) 607-617
178. Liu W., Kato M., Akhand A.A., Hayakawa A., Suzuki H., Miyata T., Kurokawa K., Hotta Y., Ishikawa N., and Nakashima I. 4-Hydroxynonenal induces a cellular redox status-related activation of the caspase cascade for apoptotic cell death. J. Cell. Sci. 113 Pt 4 (2000) 635-641
179. Liu B., Gao H.M., and Hong J.S. Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation. Environ. Health Perspect. 111 (2003) 1065-1073
180. Liu Y., Qin L., Li G., Zhang W., An L., Liu B., and Hong J. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 305 (2003) 212-218
181. Liu C.W., Giasson B.I., Lewis K.A., Lee V.M., Demartino G.N., and Thomas P.J. A precipitating role for truncated alpha-synuclein and the proteasome in alpha-synuclein aggregation: implications for pathogenesis of Parkinson disease. J. Biol. Chem. 280 (2005) 22670-22678
182. Locksley R.M., Killeen N., and Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104 (2005) 487-501
183. Luberto C., Hassler D.F., Signorelli P., Okamoto Y., Sawai H., Boros E., Hazen-Martin D.J., Obeid L.M., Hannun Y.A., and Smith G.K. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J. Biol. Chem. 277 (2002) 41128-41139
184. Lund S., Porzgen P., Mortensen A.L., Hasseldam H., Bozyczko-Coyne D., Morath S., Hartung T., Bianchi M., Ghezzi P., Bsibsi M., Dijkstra S., and Leist M. Inhibition of microglial inflammation by the MLK inhibitor CEP-1347. J. Neurochem. 92 (2005) 1439-1451
185. Maccarrone M., Melino G., and Finazzi-Agro A. Lipoxygenases and their involvement in programmed cell death. Cell Death Differ. 8 (2001) 776-784
186. MacEwan D.J. TNF receptor subtype signalling: differences and cellular consequences. Cell Signal 14 (2002) 477-492
187. Mandel S., Grunblatt E., and Youdim M. cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J. Neural Transm., Suppl. (2000) 117-124
188. Marchetti B., and Abbracchio M.P. To be or not to be (inflamed) - is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?. Trends Pharmacol. Sci. 26 (2005) 517-525
189. Marchetti L., Klein M., Schlett K., Pfizenmaier K., and Eisel U.L. Tumor necrosis factor (TNF)-mediated neuroprotection against glutamate-induced excitotoxicity is enhanced by N-methyl-d-aspartate receptor activation. Essential role of a TNF receptor 2-mediated phosphatidylinositol 3-kinase-dependent NF-kappa B pathway. J. Biol. Chem. 279 (2004) 32869-32881
190. Marshall K.A., Reist M., Jenner P., and Halliwell B. The neuronal toxicity of sulfite plus peroxynitrite is enhanced by glutathione depletion: implications for Parkinson's disease. Free Radic. Biol. Med. 27 (1999) 515-520
191. Maruyama Y., Teraoka H., Iwata H., Kazusaka A., and Fujita S. Inhibitory effects of endogenous dopaminergic neurotoxin, norsalsolinol on dopamine secretion in PC12 rat pheochromocytoma cells. Neurochem. Int. 38 (2001) 567-572
192. Mattson M.P. NF-kappaB in the survival and plasticity of neurons. Neurochem. Res. 30 (2005) 883-893
193. Mattson M.P., and Meffert M.K. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. Cell Death Differ. 13 (2006) 852-860
194. McCoy M.K., Martinez T.N., Ruhn K.A., Szymkowski D.E., Smith C.G., Botterman B.R., Tansey K.E., and Tansey M.G. Blocking soluble tumor necrosis factor signaling with dominant-negative TNF inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 26 (2006) 9365-9375
195. McGeer E.G., and McGeer P.L. The importance of inflammatory mechanisms in Alzheimer disease. Exp. Gerontol. 33 (1998) 371-378
196. McGeer P.L., and McGeer E.G. Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions. Alzheimer Dis. Assoc. Disord. 12 Suppl 2 (1998) S1-S6
197. McGeer P.L., and McGeer E.G. Inflammation and the degenerative diseases of aging. Ann. N. Y. Acad. Sci. 1035 (2004) 104-116
198. McGeer P.L., Itagaki S., Boyes B.E., and McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38 (1988) 1285-1291
199. McGeer P.L., Schwab C., Parent A., and Doudet D. Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration. Ann. Neurol. 54 (2003) 599-604
200. McGuire S.O., Ling Z.D., Lipton J.W., Sortwell C.E., Collier T.J., and Carvey P.M. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp. Neurol. 169 (2001) 219-230
201. McQualter J.L., and Bernard C.C. Multiple sclerosis: a battle between destruction and repair. J. Neurochem. 100 (2007) 295-306
202. Minghetti L. Role of inflammation in neurodegenerative diseases. Curr. Opin. Neurol. 18 (2005) 315-321
203. Minghetti L., Ajmone-Cat M.A., De Berardinis M.A., and De Simone R. Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res. Brain Res. Rev. 48 (2005) 251-256
204. Mizuno Y., Hattori N., Kitada T., Matsumine H., Mori H., Shimura H., Kubo S., Kobayashi H., Asakawa S., Minoshima S., and Shimizu N. Familial Parkinson's disease. Alpha-synuclein and parkin. Adv. Neurol. 86 (2001) 13-21
205. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., and Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165 (1994) 208-210
206. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., and Nagatsu T. Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211 (1996) 13-16
207. Mogi M., Togari A., Tanaka K., Ogawa N., Ichinose H., and Nagatsu T. Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-alpha induction. Neurosci. Lett. 268 (1999) 101-104
208. Mogi M., Togari A., Tanaka K., Ogawa N., Ichinose H., and Nagatsu T. Increase in level of tumor necrosis factor-alpha in 6-hydroxydopamine-lesioned striatum in rats is suppressed by immunosuppressant FK506. Neurosci. Lett. 289 (2000) 165-168
209. Mogi M., Togari A., Kondo T., Mizuno Y., Komure O., Kuno S., Ichinose H., and Nagatsu T. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J. Neural Transm. 107 (2000) 335-341
210. Moore D.J., West A.B., Dawson V.L., and Dawson T.M. Molecular pathophysiology of Parkinson's disease. Annu. Rev. Neurosci. 28 (2005) 57-87
211. Mrak R.E., and Griffin W.S. Glia and their cytokines in progression of neurodegeneration. Neurobiol. Aging 26 (2005) 349-354
212. Murakami T., Moriwaki Y., Kawarabayashi T., Nagai M., Ohta Y., Deguchi K., Kurata T., Morimoto N., Takehisa Y., Matsubara E., Ikeda M., Harigaya Y., Shoji M., Takahashi R., and Abe K. PINK1, a gene product of PARK6, accumulates in alpha-synucleinopathy brains. J. Neurol. Neurosurg. Psychiatry 78 (2007) 653-654
213. Nagatsu T., and Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr. Pharm. Des. 11 (2005) 999-1016
214. Nagatsu T., and Sawada M. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell. Mol. Neurobiol. 26 (2006) 781-802
215. Nagatsu T., Mogi M., Ichinose H., and Togari A. Cytokines in Parkinson's disease. J. Neural Transm. Suppl (2000) 143-151
216. Nagatsu T., Mogi M., Ichinose H., and Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. J. Neural Transm., Suppl. (2000) 277-290
217. Nakagawa T., and Schwartz J.P. Gene expression profiles of reactive astrocytes in dopamine-depleted striatum. Brain Pathol. 14 (2004) 275-280
218. Nakamura Y. Regulating factors for microglial activation. Biol. Pharm. Bull. 25 (2002) 945-953
219. Naoi M., Maruyama W., Akao Y., Zhang J., and Parvez H. Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopamine neurons. Toxicology 153 (2000) 123-141
220. Nayernouri T. Posttraumatic parkinsonism. Surg. Neurol. 24 (1985) 263-264
221. Nishimura M., Mizuta I., Mizuta E., Yamasaki S., Ohta M., Kaji R., and Kuno S. Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease. Neurosci. Lett. 311 (2001) 1-4
222. Nishimura M., Kuno S., Kaji R., Yasuno K., and Kawakami H. Glutathione-S-transferase-1 and interleukin-1beta gene polymorphisms in Japanese patients with Parkinson's disease. Mov. Disord. 20 (2005) 901-902
223. Norris E.H., and Giasson B.I. Role of oxidative damage in protein aggregation associated with Parkinson's disease and related disorders. Antioxid. Redox Signal. 7 (2005) 672-684
224. Norris E.H., Giasson B.I., Ischiropoulos H., and Lee V.M. Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications. J. Biol. Chem. 278 (2003) 27230-27240
225. Obeid L.M., Linardic C.M., Karolak L.A., and Hannun Y.A. Programmed cell death induced by ceramide. Science 259 (1993) 1769-1771
226. Ogata A., Tashiro K., Nukuzuma S., Nagashima K., and Hall W.W. A rat model of Parkinson's disease induced by Japanese encephalitis virus. J. Neurovirol. 3 (1997) 141-147
227. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., Achkar J.P., Brant S.R., Bayless T.M., Kirschner B.S., Hanauer S.B., Nunez G., and Cho J.H. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
228. Orr C.F., Rowe D.B., and Halliday G.M. An inflammatory review of Parkinson's disease. Prog. Neurobiol. 68 (2002) 325-340
229. Osterud B., and Bjorklid E. Role of monocytes in atherogenesis. Physiol. Rev. 83 (2003) 1069-1112
230. Owen A.D., Schapira A.H., Jenner P., and Marsden C.D. Oxidative stress and Parkinson's disease. Ann. N. Y. Acad. Sci. 786 (1996) 217-223
231. Owen A.D., Schapira A.H., Jenner P., and Marsden C.D. Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. J. Neural Transm., Suppl. 51 (1997) 167-173
232. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., and Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 (2004) 595-600
233. Papa S., Zazzeroni F., Bubici C., Jayawardena S., Alvarez K., Matsuda S., Nguyen D.U., Pham C.G., Nelsbach A.H., Melis T., De Smaele E., Tang W.J., D'Adamio L., and Franzoso G. Gadd45 beta mediates the NF-kappa B suppression of JNK signalling by targeting MKK7/JNKK2. Nat. Cell Biol. 6 (2004) 146-153
234. Papa S., Bubici C., Zazzeroni F., Pham C.G., Kuntzen C., Knabb J.R., Dean K., and Franzoso G. The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ. 13 (2006) 712-729
235. Paxinou E., Chen Q., Weisse M., Giasson B.I., Norris E.H., Rueter S.M., Trojanowski J.Q., Lee V.M., and Ischiropoulos H. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21 (2001) 8053-8061
236. Pearce R.K., Owen A., Daniel S., Jenner P., and Marsden C.D. Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J. Neural Transm. 104 (1997) 661-677
237. Pejovic V., Soskic V., Pan W., and Kastin A.J. Brain proteome of mice lacking the receptors for tumor necrosis factor alpha. Proteomics 4 (2004) 1461-1464
238. Picklo M.J., Amarnath V., McIntyre J.O., Graham D.G., and Montine T.J. 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites. J. Neurochem. 72 (1999) 1617-1624
239. Pizzi M., and Spano P. Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. Eur. J. Pharmacol. 545 (2006) 22-28
240. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
241. Priyadarshi A., Khuder S.A., Schaub E.A., and Priyadarshi S.S. Environmental risk factors and Parkinson's disease: a meta-analysis. Environ. Res. 86 (2001) 122-127
242. Przedborski S., and Vila M. The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease. Ann. N. Y. Acad. Sci. 991 (2003) 189-198
243. Przedborski S., Tieu K., Perier C., and Vila M. MPTP as a mitochondrial neurotoxic model of Parkinson's disease. J. Bioenerg. Biomembranes 36 (2004) 375-379
244. Przuntek H., Muller T., and Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J. Neural Transm. 111 (2004) 201-216
245. Purisai M.G., McCormack A.L., Cumine S., Li J., Isla M.Z., and Di Monte D.A. Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol. Dis. 25 (2007) 392-400
246. Rhodes K.E., Raivich G., and Fawcett J.W. The injury response of oligodendrocyte precursor cells is induced by platelets, macrophages and inflammation-associated cytokines. Neuroscience 140 (2006) 87-100
247. Rockwell P., Yuan H., Magnusson R., and Figueiredo-Pereira M.E. Proteasome inhibition in neuronal cells induces a proinflammatory response manifested by upregulation of cyclooxygenase-2, its accumulation as ubiquitin conjugates, and production of the prostaglandin PGE(2). Arch. Biochem. Biophys. 374 (2000) 325-333
248. Ross C.A., and Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 10 Supp (2004) S10-S17
249. Rousselet E., Callebert J., Parain K., Joubert C., Hunot S., Hartmann A., Jacque C., Perez-Diaz F., Cohen-Salmon C., Launay J.M., and Hirsch E.C. Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP. Exp. Neurol. 177 (2002) 183-192
250. Saavedra A., Baltazar G., and Duarte E.P. Interleukin-1beta mediates GDNF up-regulation upon dopaminergic injury in ventral midbrain cell cultures. Neurobiol. Dis. 25 (2007) 92-104
251. Sairam K., Saravanan K.S., Banerjee R., and Mohanakumar K.P. Non-steroidal anti-inflammatory drug sodium salicylate, but not diclofenac or celecoxib, protects against 1-methyl-4-phenyl pyridinium-induced dopaminergic neurotoxicity in rats. Brain Res. 966 (2003) 245-252
252. Sanchez-Pernaute R., Ferree A., Cooper O., Yu M., Brownell A.L., and Isacson O. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease. J. Neuroinflammation 1 (2004) 6
253. Sawada M., Imamura K., and Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. J. Neural Transm., Suppl. (2006) 373-381
254. Schapira A.H. Evidence for mitochondrial dysfunction in Parkinson's disease-a critical appraisal. Mov. Disord. 9 (1994) 125-138
255. Schapira A.H. Mitochondrial disease. Lancet 368 (2006) 70-82
256. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1 (1989) 1269
257. Schwab J.M., Beschorner R., Meyermann R., Gozalan F., and Schluesener H.J. Persistent accumulation of cyclooxygenase-1-expressing microglial cells and macrophages and transient upregulation by endothelium in human brain injury. J. Neurosurg. 96 (2002) 892-899
258. Selkoe D.J. Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 6 (2004) 1054-1061
259. 2. Free Radic. Biol. Med. 34 (2003) 521-530
260. Shen H.M., and Pervaiz S. TNF receptor superfamily-induced cell death: redox-dependent execution. FASEB J. 20 (2006) 1589-1598
261. Sherer T.B., Betarbet R., and Greenamyre J.T. Environment, mitochondria, and Parkinson's disease. Neuroscientist 8 (2002) 192-197
262. Sherer T.B., Betarbet R., Stout A.K., Lund S., Baptista M., Panov A.V., Cookson M.R., and Greenamyre J.T. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22 (2002) 7006-7015
263. Sherer T.B., Kim J.H., Betarbet R., and Greenamyre J.T. Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp. Neurol. 179 (2003) 9-16
264. Sherer T.B., Betarbet R., Kim J.H., and Greenamyre J.T. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci. Lett. 341 (2003) 87-90
265. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., and Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 23 (2003) 10756-10764
266. Shoji H., Watanabe M., Itoh S., Kuwahara H., and Hattori F. Japanese encephalitis and parkinsonism. J. Neurol. 240 (1993) 59-60
267. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
268. Sofic E., Lange K.W., Jellinger K., and Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142 (1992) 128-130
269. Souza J.M., Giasson B.I., Chen Q., Lee V.M., and Ischiropoulos H. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275 (2000) 18344-18349
270. Spencer J.P., Jenner P., Daniel S.E., Lees A.J., Marsden D.C., and Halliwell B. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J. Neurochem. 71 (1998) 2112-2122
271. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., and O'Callaghan J.P. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J. 16 (2002) 1474-1476
272. Sriram K., Matheson J.M., Benkovic S.A., Miller D.B., Luster M.I., and O'Callaghan J.P. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha. FASEB J. 20 (2006) 670-682
273. Sterka Jr. D., Rati D.M., and Marriott I. Functional expression of NOD2, a novel pattern recognition receptor for bacterial motifs, in primary murine astrocytes. Glia 53 (2006) 322-330
274. Stern M.B. Head trauma as a risk factor for Parkinson's disease. Mov. Disord. 6 (1991) 95-97
275. Stern M., Dulaney E., Gruber S.B., Golbe L., Bergen M., Hurtig H., Gollomp S., and Stolley P. The epidemiology of Parkinson's disease. A case-control study of young-onset and old-onset patients. Arch. Neurol. 48 (1991) 903-907
276. Stokes A.H., Hastings T.G., and Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J. Neurosci. Res. 55 (1999) 659-665
277. Streit W.J. Microglial response to brain injury: a brief synopsis. Toxicol. Pathol. 28 (2000) 28-30
278. Su X., Maguire-Zeiss K.A., Giuliano R., Prifti L., Venkatesh K., and Federoff H.J. Synuclein activates microglia in a model of Parkinson's disease. Neurobiol. Aging (2007) (May 28, Epub)
279. Sugama S., Yang L., Cho B.P., DeGiorgio L.A., Lorenzl S., Albers D.S., Beal M.F., Volpe B.T., and Joh T.H. Age-related microglial activation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res. 964 (2003) 288-294
280. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci. 30 (2007) 244-250
281. Tang B.L., and Liou Y.C. Novel modulators of amyloid-beta precursor protein processing. J. Neurochem. 100 (2007) 314-323
282. Tanner C.M. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv. Neurol. 91 (2003) 133-142
283. Tartaglia L.A., Rothe M., Hu Y.F., and Goeddel D.V. Tumor necrosis factor's cytotoxic activity is signaled by the p55 TNF receptor. Cell 73 (1993) 213-216
284. Teismann P., Vila M., Choi D.K., Tieu K., Wu D.C., Jackson-Lewis V., and Przedborski S. COX-2 and neurodegeneration in Parkinson's disease. Ann. N. Y. Acad. Sci. 991 (2003) 272-277
285. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5473-5478
286. Tetrud J.W., Langston J.W., Garbe P.L., and Ruttenber A.J. Mild parkinsonism in persons exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neurology 39 (1989) 1483-1487
287. The National Institute of Neurological Disorders and Stroke Neuroprotective Exploratory Trials in Parkinson's Disease Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66 (2006) 664-671 10.1212/01.wnl.0000201252.57661.e1
288. Thiruchelvam M., Richfield E.K., Goodman B.M., Baggs R.B., and Cory-Slechta D.A. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology 23 (2002) 621-633
289. Thorsen P., Jensen I.P., Jeune B., Ebbesen N., Arpi M., Bremmelgaard A., and Moller B.R. Few microorganisms associated with bacterial vaginosis may constitute the pathologic core: a population-based microbiologic study among 3596 pregnant women. Am. J. Obstet. Gynecol. 178 (1998) 580-587
290. Tilleux S., and Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J. Neurosci. Res. 85 (2007) 2059-2070
291. Tomas-Camardiel M., Rite I., Herrera A.J., de Pablos R.M., Cano J., Machado A., and Venero J.L. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood-brain barrier, and damage in the nigral dopaminergic system. Neurobiol. Dis. 16 (2004) 190-201
292. Tran P.B., and Miller R.J. Aggregates in neurodegenerative disease: crowds and power?. Trends Neurosci. 22 (1999) 194-197
293. Uhl G.R., Hedreen J.C., and Price D.L. Parkinson's disease: loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions. Neurology 35 (1985) 1215-1218
294. Uryu K., Giasson B.I., Longhi L., Martinez D., Murray I., Conte V., Nakamura M., Saatman K., Talbot K., Horiguchi T., McIntosh T., Lee V.M., and Trojanowski J.Q. Age-dependent synuclein pathology following traumatic brain injury in mice. Exp. Neurol. 184 (2003) 214-224
295. Valente E.M., Salvi S., Ialongo T., Marongiu R., Elia A.E., Caputo V., Romito L., Albanese A., Dallapiccola B., and Bentivoglio A.R. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 56 (2004) 336-341
296. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., and Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304 (2004) 1158-1160
297. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., and Nelson L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157 (2003) 1015-1022
298. Vawter M.P., Dillon-Carter O., Tourtellotte W.W., Carvey P., and Freed W.J. TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp. Neurol. 142 (1996) 313-322
299. Veluthakal R., Palanivel R., Zhao Y., McDonald P., Gruber S., and Kowluru A. Ceramide induces mitochondrial abnormalities in insulin-secreting INS-1 cells: potential mechanisms underlying ceramide-mediated metabolic dysfunction of the beta cell. Apoptosis 10 (2005) 841-850
300. Vila M., Jackson-Lewis V., Vukosavic S., Djaldetti R., Liberatore G., Offen D., Korsmeyer S.J., and Przedborski S. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 2837-2842
301. Wahner A.D., Sinsheimer J.S., Bronstein J.M., and Ritz B. Inflammatory cytokine gene polymorphisms and increased risk of Parkinson disease. Arch. Neurol. 64 (2007) 836-840
302. Wang M.J., Lin W.W., Chen H.L., Chang Y.H., Ou H.C., Kuo J.S., Hong J.S., and Jeng K.C. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur. J. Neurosci. 16 (2002) 2103-2112
303. Wang Y., Singh R., Lefkowitch J.H., Rigoli R.M., and Czaja M.J. Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J. Biol. Chem. 281 (2006) 15258-15267
304. Waragai M., Wei J., Fujita M., Nakai M., Ho G.J., Masliah E., Akatsu H., Yamada T., and Hashimoto M. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem. Biophys. Res. Commun. 345 (2006) 967-972
305. Weller C., Oxlade N., Dobbs S.M., Dobbs R.J., Charlett A., and Bjarnason I.T. Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunol. Med. Microbiol. 44 (2005) 129-135
306. Weller C., Charlett A., Oxlade N.L., Dobbs S.M., Dobbs R.J., Peterson D.W., and Bjarnason I.T. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism: Part 3. Predicted probability and gradients of severity of idiopathic parkinsonism based on H. pylori antibody profile. Helicobacter 10 (2005) 288-297
307. Wersinger C., and Sidhu A. Inflammation and Parkinson's disease. Curr. Drug Targets Inflamm. Allergy 1 (2002) 221-242
308. Wersinger C., and Sidhu A. An inflammatory pathomechanism for Parkinson's disease?. Curr. Med. Chem. 13 (2006) 591-602
309. Whitton P.S. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br. J. Pharmacol. 150 (2007) 963-976
310. Wilms H., Claasen J., Rohl C., Sievers J., Deuschl G., and Lucius R. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiol. Dis. 14 (2003) 417-424
311. Wilms H., Rosenstiel P., Sievers J., Deuschl G., Zecca L., and Lucius R. Activation of microglia by human neuromelanin is NF-κB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. Faseb J. 17 (2003) 500-502
312. Wojtera M., Sikorska B., Sobow T., and Liberski P.P. Microglial cells in neurodegenerative disorders. Folia Neuropathol. 43 (2005) 311-321
313. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771
314. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 12 (2006) 1005-1015
315. Wyss-Coray T., and Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 35 (2002) 419-432
316. Yamagata K., Andreasson K.I., Kaufmann W.E., Barnes C.A., and Worley P.F. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11 (1993) 371-386
317. Yasuhara R., Miyamoto Y., Akaike T., Akuta T., Nakamura M., Takami M., Morimura N., Yasu K., and Kamijo R. Interleukin-1beta induces death in chondrocyte-like ATDC5 cells through mitochondrial dysfunction and energy depletion in a reactive nitrogen and oxygen species-dependent manner. Biochem. J. 389 (2005) 315-323
318. Yazdani U., German D.C., Liang C.L., Manzino L., Sonsalla P.K., and Zeevalk G.D. Rat model of Parkinson's disease: chronic central delivery of 1-methyl-4-phenylpyridinium (MPP+). Exp. Neurol. 200 (2006) 172-183
319. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., and Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2696-2701
320. Youdim M.B., and Buccafusco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. 26 (2005) 27-35
321. Zecca L., Zucca F.A., Albertini A., Rizzio E., and Fariello R.G. A
322. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.J., Graham D.G., and Montine T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 154 (1999) 1423-1429
323. Zhang W., Wang T., Pei Z., Miller D.S., Wu X., Block M.L., Wilson B., Zhou Y., Hong J.S., and Zhang J. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J. 19 (2005) 533-542
324. Zhang L., Dawson V.L., and Dawson T.M. Role of nitric oxide in Parkinson's disease. Pharmacol. Ther. 109 (2006) 33-41
325. Zhao Y., Li S., Childs E.E., Kuharsky D.K., and Yin X.M. Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-alpha-induced liver injury. J. Biol. Chem. 276 (2001) 27432-27440
326. Zhou Y., Su Y., Li B., Liu F., Ryder J.W., Wu X., Gonzalez-DeWhitt P.A., Gelfanova V., Hale J.E., May P.C., Paul S.M., and Ni B. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302 (2003) 1215-1217
327. Zimprich A., Muller-Myhsok B., Farrer M., Leitner P., Sharma M., Hulihan M., Lockhart P., Strongosky A., Kachergus J., Calne D.B., Stoessl J., Uitti R.J., Pfeiffer R.F., Trenkwalder C., Homann N., Ott E., Wenzel K., Asmus F., Hardy J., Wszolek Z., and Gasser T. The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am. J. Hum. Genet. 74 (2004) 11-19
328. Zucca F.A., Giaveri G., Gallorini M., Albertini A., Toscani M., Pezzoli G., Lucius R., Wilms H., Sulzer D., Ito S., Wakamatsu K., and Zecca L. The neuromelanin of human substantia nigra: physiological and pathogenic aspects. Pigment Cell Res 17 (2004) 610-617